The Trump administration recently cancelled billions of dollars in funding to the NIH. Healthcare experts say the funding cuts will delay the pace of medical research in the U.S. — which will not only hamper the commercialization of life-saving treatments, but could also hurt the country’s position as a global leader in healthcare and technology.
President Donald Trump selected Susan Monarez — the current acting director of the Centers for Disease Control and Prevention — to lead the agency going forward. This nomination replaces one that the White House withdrew on March 13, after it became clear that physician and former Republican congressman Dave Weldon would not receive enough Senate votes to be confirmed.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Exactly what the administration is ultimately able to accomplish will be anyone’s guess, but here are some key policy and market shifts healthcare leaders and their PR teams should watch closely and be prepared to communicate around.
CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.
In a new brief, the Purchaser Business Group on Health called for policy changes that address healthcare costs and improve access to high-quality care.
As President Trump would have most certainly learned on his first day at Wharton, you really have to spend money to make money. If you want to make America truly a world leader, why on earth would you stifle the institution that contributed an estimated $92.89 billion to the US economy in 2023 alone and has produced over 170 Nobel Laureates since its inception?
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
The impact of private equity investments in healthcare under the new administration is multifaceted. While deregulation and business-friendly policies could stimulate investment and drive innovation, there are significant concerns about the potential negative effects on healthcare quality and access.
President-elect Donald Trump recently appointed former Paypal executive David Sacks as the White House’s first-ever czar for AI and cryptocurrency. Ryan Tarzy — CEO of Avandra Imaging, a federated network for de-identified imaging data — thinks this appointment could help accelerate the pace of innovation in the healthcare industry.
When it comes to the effects that the upcoming Trump presidency will have on healthcare, attendees' attitudes ranged from cautiously optimistic to fairly anxious. Some of the issues they highlighted included mental health parity, telehealth prescribing flexibilities, and the role of Robert F. Kennedy Jr.
The country is just one week into the Covid-19 vaccine rollout, and it has become clear that America is ill-prepared for a mass vaccination campaign of this scale.
If you’re helping clients navigate big changes—from the surge in GLP-1 demand to AI to the growing pressure to demonstrate ROI – we want your thoughts.
The agency said its own analysis of the EUA, issued in March, and emerging data showed the drug and a related compound, chloroquine, were unlikely to be effective. The Trump administration had aggressively promoted the drug despite a lack of supporting scientific evidence.
The study, published in The Lancet, found a possible association between hydroxychloroquine and chloroquine and heart arrhythmias and death. Meanwhile, SingleCare saw a as much as a 22% increase in scripts filled for hydroxychloroquine following Trump's remarks last week.
News media reported that Moncef Slaoui would divest his shares in Moderna, which netted him at least $3 million after the company reported promising preliminary data on its Covid-19 vaccine Monday.
Bloomberg reported Wednesday that the Trump administration is launching the effort, which it compared to the Manhattan Project, to shorten the length of time it would take to develop a vaccine for the disease.
Politico reported Tuesday that the Trump administration is trying to secure an emergency use authorization from the Food and Drug Administration for Fujifilm's Avigan. The FDA gave an EUA to two unproven antimalarial drugs over the weekend.